ENXTPA:SANPharmaceuticals
Is Sanofi (ENXTPA:SAN) Cheap Following MenQuadfi Approval For Infants?
EC approval for MenQuadfi expansion puts Sanofi stock in focus
The European Commission has approved an expanded indication for MenQuadfi, allowing Sanofi (ENXTPA:SAN) to offer its meningococcal vaccine to infants from six weeks of age, extending coverage beyond the previous 12 months and older group.
This change targets one of the highest risk populations for invasive meningococcal disease and is supported by comprehensive clinical data on immunogenicity and safety. For investors, it raises...